GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
You do not currently have access to this article. GLP-1 Receptor Agonists and Risk of Adverse Cerebrovascular Outcomes in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled...
Conclusion: GLP-1RAs, precisely longer acting formulations, reduced ischemic cerebrovascular events in T2DM. Observed benefits were significantly higher in patients with shorter T2DM duration and higher eGFR.
Share
Prioritizing obesity treatment: expanding the role of cardiologists to improve cardiovascular health and outcomes
s for obesity, which are associated with numerous health benefits. Modest weight reductions of 5-10% improve cardiovascular risk factors, with greater weight loss bringing about greater benefits. Anti-obesity medications can...
Relevance: There are several treatment options for obesity, which are associated with numerous health benefits. Modest weight reductions of 5–10% improve cardiovascular risk factors, with greater weight loss bringing about greater benefits. Anti-obesity medications can support weight reduction when lifestyle modifications alone are...
Share
Treatment with semaglutide, a GLP-1 receptor agonist, improves extracellular matrix remodeling in the pancreatic islet of diet-induced obese mice
Source : https://www.sciencedirect.com/science/article/abs/pii/S0024320523001364?via=ihub
Available online 14 February 2023, 121502 Author links open overlay panel Luiz E. Macedo Cardoso , Thatiany Souza Marinho , Fabiane Ferreira Martins , Marcia Barbosa Aguila , Carlos A....
Significance: Semaglutide improved the turnover of islet heparan sulfate proteoglycans, hyaluronan, chondroitin sulfate proteoglycans, and collagens in the islet ECM. Such changes should contribute to restoring a healthy islet functional milieu and should reduce the formation of cell-damaging amyloid deposits. Our findings also provide...
Share
Once-weekly semaglutide use in patients with type 2 diabetes: real-world data from the SURE Italy observational study - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36789682/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: In routine clinical practice in Italy, patients with T2D treated with OW semaglutide for 30 weeks achieved clinically significant improvements in HbA1c , BW and other outcomes. This article is protected by copyright. All rights reserved.
Share
Separate and combined effects of semaglutide and empagliflozin on kidney oxygenation and perfusion in people with type 2 diabetes: a randomised trial - Diabetologia
Source : https://link.springer.com/article/10.1007/s00125-023-05876-w
Aims/hypothesis Glucagon-like peptide-1 receptor agonists (GLP-1ras) and sodium-glucose cotransporter 2 inhibitors (SGLT2is) have shown kidney-protective effects. Improved kidney oxygenation and haemodynamic changes are suggested mechanisms; however, human data are scarce....
Conclusions/Interpretation: Our hypothesis, that semaglutide, empagliflozin or their combination improve kidney oxygenation, was rejected. On the contrary, empagliflozin induced a reduction in medullary kidney oxygenation. Semaglutide substantially reduced kidney perfusion without affecting oxygenation.
Share